Medical device start-up pioneering minimally-invasive treatments for PAD focused on SFA disease. Currently enrolling TORUS-2 and DETOUR-2 Clinical Trials
Total raised: $60M
Investors 1
| Date | Name | Website |
| - | Seroba Lif... | seroba-lif... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2019 | - | $60M | - |
Mentions in press and media 14
| Date | Title | Description |
| 15.01.2019 | Term Sheet — Tuesday, January 15 | BAKKT UP Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop On Monday, Bakkt, which was launched by the owner of the New York Stock Exchange, announced the acquisition of assets own... |
| 14.01.2019 | PQ Bypass Announces $60M Financing | SUNNYVALE, CA, Medical device company dedicated to advancing treatment options for patients with peripheral arterial disease has raised $60 million in equity financing. >> Click here for more funding data on PQ Bypass >> To ... |
| 11.01.2019 | PQ Bypass raises $60M to fund PAD Detour graft tech W h i t e p a p e r Weighing the Costs: | PQ Bypass has gathered $60 million in equity financing to move forward with its minimally invasive technology for treating long blockages in leg arteries caused by peripheral artery disease. Sponsored by Agilent Technologies How would you l... |
| 11.01.2019 | PQ Bypass raises $60M to fund PAD Detour graft tech | PQ Bypass has gathered $60 million in equity financing to move forward with its minimally invasive technology for treating long blockages in leg arteries caused by peripheral artery disease. The round—led by Deerfield Management, with parti... |
| 08.01.2019 | PQ Bypass Receives $60M in Equity Financing | PQ Bypass, Inc., a Sunnyvale, Calif.-based medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), is to receive $60m in equity financing. The round – which also allowed the compa... |
| 08.01.2019 | PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease | Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries SUNNYVALE, Calif.–(BUSINESS WIRE)–January 8, 2019– PQ Bypass, Inc., a medical device company dedicated to advan... |
| - | PQ Bypass Sold to Endologix | Dublin, Ireland. 14 April 2021. Seroba’s portfolio company, PQ Bypass Inc., a medical device pioneer advancing the treatment of complex peripheral artery disease (PAD), has been acquired by Endologix, a global medical device company wholly ... |
| - | PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study. | Milpitas, California & Dublin, Ireland. October 8, 2019. PQ Bypass Announces Unconditional IDE Approval from U.S. FDA to Start TORUS SFA Stent Graft Pivotal Study (TORUS-2) Seroba’s portfolio company, PQ Bypass, Inc., a clinical-stage ... |
| - | PQ Bypass Reports Positive 12-Month Results. | Milpitas, California. 28 June 2018. Results from the DETOUR I Trial evaluating the PQ Bypass DETOUR System for percutaneous bypass showed promising 12-month durability for patients with extremely long blockages in the superficial femoral ar... |
| - | Doctors Perform ‘Bypass’ Without Surgery. | Little Rock, Arkansas. 2 March 2018. Seroba’s investee company, PQ Bypass was making eye-catching headlines in the USA this week. Arkansas Heart Hospital is the first U.S. hospital to perform the DETOUR procedure and the story was carried o... |
Show more